Biotechnology
Compare Stocks
2 / 10Stock Comparison
MDXG vs APOG
Revenue, margins, valuation, and 5-year total return — side by side.
Construction
MDXG vs APOG — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Biotechnology | Construction |
| Market Cap | $548M | $787M |
| Revenue (TTM) | $389M | $1.40B |
| Net Income (TTM) | $31M | $54M |
| Gross Margin | 81.0% | 22.7% |
| Operating Margin | 10.2% | 6.7% |
| Forward P/E | 295.2x | 10.6x |
| Total Debt | $23M | $286M |
| Cash & Equiv. | $166M | $40M |
MDXG vs APOG — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| MiMedx Group, Inc. (MDXG) | 100 | 102.8 | +2.8% |
| Apogee Enterprises,… (APOG) | 100 | 177.1 | +77.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MDXG vs APOG
Each card shows where this stock fits in a portfolio — not just who wins on paper.
MDXG carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.22
- Rev growth 20.0%, EPS growth 14.3%, 3Y rev CAGR 16.1%
- Lower volatility, beta 1.22, Low D/E 8.8%, current ratio 4.32x
APOG is the clearest fit if your priority is long-term compounding.
- 10.5% 10Y total return vs MDXG's -48.5%
- Lower P/E (10.6x vs 295.2x)
- 2.8% yield; 14-year raise streak; the other pay no meaningful dividend
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 20.0% revenue growth vs APOG's 3.2% | |
| Value | Lower P/E (10.6x vs 295.2x) | |
| Quality / Margins | 7.9% margin vs APOG's 3.9% | |
| Stability / Safety | Beta 1.22 vs APOG's 1.25, lower leverage | |
| Dividends | 2.8% yield; 14-year raise streak; the other pay no meaningful dividend | |
| Momentum (1Y) | -2.8% vs MDXG's -47.1% | |
| Efficiency (ROA) | 9.7% ROA vs APOG's 4.8%, ROIC 42.3% vs 8.1% |
MDXG vs APOG — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
MDXG vs APOG — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
MDXG leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
APOG is the larger business by revenue, generating $1.4B annually — 3.6x MDXG's $389M. Profitability is closely matched — net margins range from 7.9% (MDXG) to 3.9% (APOG). On growth, APOG holds the edge at +1.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $389M | $1.4B |
| EBITDAEarnings before interest/tax | $53M | $57M |
| Net IncomeAfter-tax profit | $31M | $54M |
| Free Cash FlowCash after capex | $66M | $95M |
| Gross MarginGross profit ÷ Revenue | +81.0% | +22.7% |
| Operating MarginEBIT ÷ Revenue | +10.2% | +6.7% |
| Net MarginNet income ÷ Revenue | +7.9% | +3.9% |
| FCF MarginFCF ÷ Revenue | +17.0% | +6.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | -33.1% | +1.6% |
| EPS Growth (YoY)Latest quarter vs prior year | -2.4% | +6.1% |
Valuation Metrics
Evenly matched — MDXG and APOG each lead in 3 of 6 comparable metrics.
Valuation Metrics
At 11.5x trailing earnings, MDXG trades at a 21% valuation discount to APOG's 14.5x P/E. On an enterprise value basis, MDXG's 5.1x EV/EBITDA is more attractive than APOG's 21.9x.
| Metric | ||
|---|---|---|
| Market CapShares × price | $548M | $787M |
| Enterprise ValueMkt cap + debt − cash | $405M | $1.0B |
| Trailing P/EPrice ÷ TTM EPS | 11.53x | 14.52x |
| Forward P/EPrice ÷ next-FY EPS est. | 295.20x | 10.64x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.43x |
| EV / EBITDAEnterprise value multiple | 5.14x | 21.95x |
| Price / SalesMarket cap ÷ Revenue | 1.31x | 0.56x |
| Price / BookPrice ÷ Book value/share | 2.15x | 1.53x |
| Price / FCFMarket cap ÷ FCF | 7.51x | 8.27x |
Profitability & Efficiency
MDXG leads this category, winning 8 of 9 comparable metrics.
Profitability & Efficiency
MDXG delivers a 12.9% return on equity — every $100 of shareholder capital generates $13 in annual profit, vs $11 for APOG. MDXG carries lower financial leverage with a 0.09x debt-to-equity ratio, signaling a more conservative balance sheet compared to APOG's 0.56x. On the Piotroski fundamental quality scale (0–9), APOG scores 7/9 vs MDXG's 5/9, reflecting strong financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | +12.9% | +10.8% |
| ROA (TTM)Return on assets | +9.7% | +4.8% |
| ROICReturn on invested capital | +42.3% | +8.1% |
| ROCEReturn on capital employed | +25.7% | +9.7% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 7 |
| Debt / EquityFinancial leverage | 0.09x | 0.56x |
| Net DebtTotal debt minus cash | -$144M | $247M |
| Cash & Equiv.Liquid assets | $166M | $40M |
| Total DebtShort + long-term debt | $23M | $286M |
| Interest CoverageEBIT ÷ Interest expense | 25.32x | 5.97x |
Total Returns (Dividends Reinvested)
APOG leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in APOG five years ago would be worth $11,292 today (with dividends reinvested), compared to $3,712 for MDXG. Over the past 12 months, APOG leads with a -2.8% total return vs MDXG's -47.1%. The 3-year compound annual growth rate (CAGR) favors APOG at -0.0% vs MDXG's -14.1% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -43.1% | -1.3% |
| 1-Year ReturnPast 12 months | -47.1% | -2.8% |
| 3-Year ReturnCumulative with dividends | -36.6% | -0.1% |
| 5-Year ReturnCumulative with dividends | -62.9% | +12.9% |
| 10-Year ReturnCumulative with dividends | -48.5% | +10.5% |
| CAGR (3Y)Annualised 3-year return | -14.1% | -0.0% |
Risk & Volatility
Evenly matched — MDXG and APOG each lead in 1 of 2 comparable metrics.
Risk & Volatility
MDXG is the less volatile stock with a 1.22 beta — it tends to amplify market swings less than APOG's 1.25 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. APOG currently trades 73.2% from its 52-week high vs MDXG's 46.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.22x | 1.25x |
| 52-Week HighHighest price in past year | $7.99 | $49.99 |
| 52-Week LowLowest price in past year | $3.02 | $30.75 |
| % of 52W HighCurrent price vs 52-week peak | +46.2% | +73.2% |
| RSI (14)Momentum oscillator 0–100 | 49.3 | 53.6 |
| Avg Volume (50D)Average daily shares traded | 1.4M | 253K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates MDXG as "Buy" and APOG as "Hold". Consensus price targets imply 171.0% upside for MDXG (target: $10) vs 92.7% for APOG (target: $71). APOG is the only dividend payer here at 2.83% yield — a key consideration for income-focused portfolios.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold |
| Price TargetConsensus 12-month target | $10.00 | $70.50 |
| # AnalystsCovering analysts | 15 | 6 |
| Dividend YieldAnnual dividend ÷ price | — | +2.8% |
| Dividend StreakConsecutive years of raises | — | 14 |
| Dividend / ShareAnnual DPS | — | $1.04 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.6% | +1.9% |
MDXG leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). APOG leads in 1 (Total Returns). 2 tied.
MDXG vs APOG: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is MDXG or APOG a better buy right now?
For growth investors, MiMedx Group, Inc.
(MDXG) is the stronger pick with 20. 0% revenue growth year-over-year, versus 3. 2% for Apogee Enterprises, Inc. (APOG). MiMedx Group, Inc. (MDXG) offers the better valuation at 11. 5x trailing P/E (295. 2x forward), making it the more compelling value choice. Analysts rate MiMedx Group, Inc. (MDXG) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — MDXG or APOG?
On trailing P/E, MiMedx Group, Inc.
(MDXG) is the cheapest at 11. 5x versus Apogee Enterprises, Inc. at 14. 5x. On forward P/E, Apogee Enterprises, Inc. is actually cheaper at 10. 6x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — MDXG or APOG?
Over the past 5 years, Apogee Enterprises, Inc.
(APOG) delivered a total return of +12. 9%, compared to -62. 9% for MiMedx Group, Inc. (MDXG). Over 10 years, the gap is even starker: APOG returned +10. 5% versus MDXG's -48. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — MDXG or APOG?
By beta (market sensitivity over 5 years), MiMedx Group, Inc.
(MDXG) is the lower-risk stock at 1. 22β versus Apogee Enterprises, Inc. 's 1. 25β — meaning APOG is approximately 3% more volatile than MDXG relative to the S&P 500. On balance sheet safety, MiMedx Group, Inc. (MDXG) carries a lower debt/equity ratio of 9% versus 56% for Apogee Enterprises, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — MDXG or APOG?
By revenue growth (latest reported year), MiMedx Group, Inc.
(MDXG) is pulling ahead at 20. 0% versus 3. 2% for Apogee Enterprises, Inc. (APOG). On earnings-per-share growth, the picture is similar: MiMedx Group, Inc. grew EPS 14. 3% year-over-year, compared to -35. 2% for Apogee Enterprises, Inc.. Over a 3-year CAGR, MDXG leads at 16. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — MDXG or APOG?
MiMedx Group, Inc.
(MDXG) is the more profitable company, earning 11. 6% net margin versus 3. 9% for Apogee Enterprises, Inc. — meaning it keeps 11. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MDXG leads at 15. 3% versus 6. 0% for APOG. At the gross margin level — before operating expenses — MDXG leads at 82. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is MDXG or APOG more undervalued right now?
On forward earnings alone, Apogee Enterprises, Inc.
(APOG) trades at 10. 6x forward P/E versus 295. 2x for MiMedx Group, Inc. — 284. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MDXG: 171. 0% to $10. 00.
08Which pays a better dividend — MDXG or APOG?
In this comparison, APOG (2.
8% yield) pays a dividend. MDXG does not pay a meaningful dividend and should not be held primarily for income.
09Is MDXG or APOG better for a retirement portfolio?
For long-horizon retirement investors, Apogee Enterprises, Inc.
(APOG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 25), 2. 8% yield). Both have compounded well over 10 years (APOG: +10. 5%, MDXG: -48. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between MDXG and APOG?
These companies operate in different sectors (MDXG (Healthcare) and APOG (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: MDXG is a small-cap high-growth stock; APOG is a small-cap deep-value stock. APOG pays a dividend while MDXG does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.